Dr Reddy's Laboratories Ltd has entered the inhaler segment in India with the launch of 'Combihale' – a combination of a steroid and a long acting bronchodilator.
'Combihale' is used in the treatment of asthma and is available in two combinations, Combihale FF (Formoterol + Fluticasone) and Combihale FB (Formoterol + Budesonide).
Combihale would be available along with 'Redihaler', a dry powder inhalation device that was designed in-house and which will initially be given free of cost with Combihale.Combihale is a combination of a steroid and a long acting bronchodilator Combihale range of inhalational drugs are dispensed either through dry powder (DPI) or metered dose inhaler (MDI) forms. Upon oral inhalation, they selectively deposit the drug at the site where their action is needed.
According to the company's press release, Combihale is available in the market in both dry powder inhaler 2 X 15's blister caps and metered dose inhaler of 120 doses.
Inhaler market is currently valued at Rs 473 crore growing at over 17 per cent annually, according to ORG IMS.